Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

Discover how intelligent protection relays are evolving beyond fault detection to deliver real-time insights, power quality ...

Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational ...

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.45 per share a year ago. These ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...

VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3 Study met primary endpoint of statistically significant weight ...

A Roche obesity drug designed to hit two targets led to weight loss that is competitive with other drugs in its class, but from a development standpoint, the drug candidate still trails rival ...

Roche obesity drug shows 22.5% weight loss in Phase-II trial Roche focuses on catching Lilly in $150 billion obesity market Investors lukewarm on CT-388 results in crowded market The company said on ...